

Bederra Corporation Receives Regulatory Approval to Practice Nuclear Medicine in Texas

On Thursday May 7, 2009, 9:45 am EDT

HOUSTON, TX--(MARKET WIRE)--May 7, 2009 -- Bederra Corporation (Other OTC:[BEDA.PK](#) - News), a medical imaging and diagnostic Company, is pleased to announce it has received approval from the State of Texas to provide Nuclear Medicine services.

The company previously announced a partnership with Advanced Nuclear Consultants, LLC on August 12th, 2008. With State licensing approval completed, the company can now move forward on this joint venture. Lumar Imaging, Inc., a wholly owned subsidiary of Bederra Corp., will install a state-of-the-art nuclear gamma camera to provide imaging services for Cardiac, Bone, Brain, Thyroid, Gastrointestinal and a variety of other imaging tests.

Nuclear imaging is a non-invasive way for Doctors to obtain the information they need to make an accurate diagnosis. By providing this new service, the company expects to increase its yearly revenue by over \$1M and to increase the number of physician referrals for its other services.

Advanced Nuclear Consultants, LLC is based in Houston, Texas and provides national sales, service and technical support for nuclear imaging systems. The company specializes in nuclear medicine consulting for private practice, diagnostic imaging centers and hospitals. For more information, visit <http://www.ancmmedical.com>.

About Bederra Corp.

<http://www.bederra.com>

Bederra Corporation, through its wholly owned subsidiaries Diagnos, Inc. and Lumar Imaging, Inc., provides multiple modality diagnostic medical imaging services to the greater Houston area and the world famous Texas Medical Center. The Company's business strategy is to continue to expand its current operations and seek out additional acquisitions that will complement its core offerings.

Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products and services in development, including any planned acquisitions, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The results anticipated by any or all of these forward-looking statements may not occur. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectations.